| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,183 |
2,155 |
$386K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,421 |
1,373 |
$379K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,559 |
1,438 |
$110K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
281 |
275 |
$94K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
708 |
699 |
$77K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
413 |
398 |
$59K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
334 |
333 |
$24K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
336 |
312 |
$23K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
317 |
303 |
$18K |
| 80053 |
Comprehensive metabolic panel |
724 |
693 |
$16K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
808 |
564 |
$12K |
| 36415 |
Collection of venous blood by venipuncture |
852 |
827 |
$11K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
322 |
322 |
$9K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
165 |
162 |
$8K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
322 |
321 |
$8K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
148 |
141 |
$7K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
135 |
133 |
$7K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
39 |
39 |
$5K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
779 |
747 |
$5K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
60 |
60 |
$5K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
221 |
220 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
260 |
260 |
$4K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
102 |
100 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
263 |
255 |
$4K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
18 |
17 |
$2K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
68 |
38 |
$2K |
| 87481 |
|
47 |
29 |
$1K |
| 87641 |
|
40 |
39 |
$1K |
| 87500 |
|
40 |
39 |
$1K |
| 83874 |
|
54 |
52 |
$685.06 |
| 84484 |
|
54 |
52 |
$661.21 |
| 87420 |
|
53 |
52 |
$646.61 |
| 82553 |
|
54 |
52 |
$612.33 |
| 84512 |
|
54 |
52 |
$525.86 |
| 83605 |
|
51 |
50 |
$514.50 |
| 83735 |
|
87 |
83 |
$494.51 |
| 81003 |
|
191 |
190 |
$344.77 |
| 84100 |
|
81 |
77 |
$331.47 |
| 82550 |
|
53 |
51 |
$329.63 |
| 86403 |
|
12 |
12 |
$112.86 |
| 81025 |
|
14 |
14 |
$107.24 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
16 |
14 |
$87.04 |
| 94761 |
|
114 |
112 |
$15.05 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
34 |
34 |
$3.15 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
194 |
185 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
25 |
24 |
$0.00 |